摘要:
The compound represented by the following general formula is useful as a light emitting material. Ar 1 represents an arylene group, Ar 2 and Ar 3 represent an aryl group, and R 1 to R 8 represent a hydrogen atom or a substituent, provided that at least one of R 1 to R 8 represents a diarylamino group.
摘要翻译:由以下通式表示的化合物可用作发光材料。 Ar 1表示亚芳基,Ar 2和Ar 3表示芳基,R 1〜R 8表示氢原子或取代基,条件是R 1〜R 8中的至少一个表示二芳基氨基。
摘要:
An organic electroluminescence element includes: a first electrode and a second electrode, a plurality of light emitting units stacked one on top of another between the first electrode and the second electrode and each having a light emitting layer formed by using an organic material, and a transparent conductive layer arranged between the plurality of light emitting units. The transparent conductive layer is formed by using silver or an alloy containing silver as a main component, and is arranged adjacent to a nitrogen-containing layer formed by using a compound containing nitrogen atom.
摘要:
An aromatic amine derivative represented by formula (1):
wherein L 1 , L 2 , Ar 1 , Ar 2 , R 1 , R 2 , a, b, and Q are as defined in the specification. An organic electroluminescence device having at least one organic thin film layer which includes the aromatic amine derivative has high emission efficiency and long lifetime.
摘要:
The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.
摘要:
This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
摘要:
The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.
摘要:
Compounds having the structure: are HIV reverse transcriptase inhibitors, wherein A, X, Y, Z, R1 and R2 are defined herein. The compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
摘要:
This invention relates to compounds of general formula (I) :
wherein R 1 and R 3 may be the same or different and each independently represents a group -L 1 -R 5 [where L 1 is a direct bond, a straight or branched C 1-6 alkylene chain, a straight or branched C 2-6 alkenylene chain, a straight or branched C 2-6 alkynylene chain or a straight or branched C 1-6 alkylene chain containing an oxygen or sulfur atom, a phenylene, imino (-NH-) or alkylimino linkage, or a sulfinyl or sulfonyl group, in which each of the alkylene, alkenylene and alkynylene chains may be optionally substituted, the substituents chosen from alkoxy, aryl, carboxy, cyano, cycloalkyl, halogen, heteroaryl, hydroxyl, or oxo; and R 5 represents hydrogen, aryl, aroyl, carboxy or an acid bioisostere, cyano, cycloalkyl, cycloalkenyl, heterocycloalkyl, heteroaryl, arylalkoxycarbonyl, -NH-C(=O)-NH 2 , -C=N-O-C(=O)-NH 2 , -C(=O)-NY 1 Y 2 , -NY 1 SO 2 aryl, -NHR 6 , -SR 6 , or -OR 6 ]; R 2 and R 4 may be the same or different and are each independently hydrogen or alkyl; or R 2 and R 4 together form a bond; or R 1 and R 2 , or R 1 and R 3 , or R 3 and R 4 together with the carbon atom(s) to which they are attached form a 3 to 8 membered cycloalkyl or cycloalkenyl ring, optionally substituted by alkyl, arylalkyl, or heteroarylalkyl, and which may optionally contain a heteroatom selected from O, S or NR 6 ; or R 1 and R 3 together with the carbon atoms to which they are attached form a heteroaryl ring; Y represents tetrazolyl, 3,5-dioxo-1,2,4-oxadiazolidinyl, 3-hydroxyisoxazolyl or 3-hydroxy-1-methylpyrazolyl; A 1 represents a direct bond, a straight or branched C 1-4 alkylene chain or a NR 6 group; Ar is a group chosen from :
and
and n is 0, 1 or 2; and N-oxides thereof, and their prodrugs, pharmaceutically acceptable salts, and solvates (e.g. hydrates), thereof. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.